

Nonalcoholic Fatty Liver Disease in the Era of MAFLD: Emerging Insights into Mechanisms, Diagnosis, and Personalized Management

Jampala Raghu Ram^{1*}, Obaid Alhilali¹, Mohammed Ashfaq Hussain¹, Mohammed Abdul Farhan¹

¹Sultan Ul Uloom College of Pharmacy, Mount Pleasant, Banjara Hills, Road No: 3, Hyderabad.500034

*Corresponding Email: raghuram143ind@gmail.com

Abstract:

Nonalcoholic fatty liver disease (NAFLD) has become the most prevalent chronic liver disorder globally, affecting over 30% of adults. It is increasingly recognized as a multisystem disease with significant cardiometabolic and oncologic consequences. Recent advances between 2021 and 2025 have substantially transformed its conceptual understanding, diagnosis, and clinical management. **Objective:** This review aims to critically evaluate global progress in NAFLD research and management from 2021 to 2025, with emphasis on epidemiology, pathophysiology, diagnostic innovations, therapeutic developments, and the emergence of precision hepatology, while addressing the transition toward metabolic dysfunction-associated fatty liver disease (MAFLD). **Methods:** A comprehensive literature search was conducted across PubMed, Scopus, and Web of Science databases, covering studies published between **June 2021 and December 2025**. Relevant clinical trials, guidelines, and high-impact research articles were systematically analyzed across key domains including epidemiology, molecular mechanisms, diagnostics, therapeutics, and public health strategies. **Results:** The global prevalence of NAFLD has increased across diverse populations, including pediatric, elderly, lean, and socioeconomically disadvantaged groups. The MAFLD terminology has gained traction for better reflecting metabolic dysfunction, although debates persist. Mechanistic insights highlight the roles of insulin resistance, lipotoxicity, mitochondrial dysfunction, impaired autophagy, and gut microbiota dysbiosis. Advances in genomics and epigenetics have identified key variants such as *PNPLA3* and *TM6SF2*, along with circulating biomarkers including miR-122 and Pro-C3. Non-invasive diagnostic tools, particularly imaging modalities and artificial intelligence-based systems, are increasingly replacing liver biopsy. Although no pharmacological therapy has yet received full regulatory approval, several agents, including obeticholic acid, resmetirom, lanifibranor, and semaglutide, are in advanced stages of clinical development. Lifestyle modification remains the cornerstone of management. NAFLD is strongly associated with increased risk of cardiovascular disease, type 2 diabetes, chronic kidney disease, and malignancies. Emerging precision hepatology approaches integrating multi-omics, artificial intelligence, and digital health technologies are enabling personalized disease management. **Conclusion:** NAFLD is evolving from a liver-specific disorder into a global multisystem health challenge. Despite significant advances, key challenges remain in standardizing diagnostic criteria, ensuring equitable access to therapies, and addressing global health disparities. The integration of precision medicine, digital technologies, and public health strategies holds promise for reducing the burden of NAFLD in the coming decade.

Keywords

NAFLD; MAFLD; NASH; fibrosis; metabolic syndrome; gut-liver axis; genomics; non-invasive diagnostics; biomarkers; artificial intelligence; precision hepatology; global health

Received: March. 17, 2026

Revised: April 30, 2026

Accepted: June 21, 2026

Published: July 09, 2026

DOI: <https://doi.org/10.64063/3049-1681.vol3.issue7.000282>

This is an Open Access article distributed under the terms of the Creative Commons Attribution (CC BY NC), which permits unrestricted use, distribution, and reproduction in any medium, as long as the original authors and source are cited. No permission is required from the authors or the publishers. (<https://creativecommons.org/licenses/by-nc/4.0/>)

1. Introduction

Definition and Clinical Relevance of NAFLD/NASH

Nonalcoholic fatty liver disease (NAFLD) represents a spectrum of hepatic conditions characterized by the accumulation of fat in more than 5% of hepatocytes in individuals who consume little or no alcohol (less than 20 g/day in women and 30 g/day in men). NAFLD encompasses two major histological subtypes: simple steatosis (nonalcoholic fatty liver, NAFL) and nonalcoholic steatohepatitis (NASH). NASH is a progressive form of the disease marked by hepatocellular injury, inflammation, and varying degrees of fibrosis that may eventually lead to cirrhosis, liver failure, or hepatocellular carcinoma (HCC)¹.

NAFLD is closely linked to metabolic comorbidities, such as obesity, insulin resistance, type 2 diabetes mellitus (T2DM), dyslipidemia, and hypertension. Given these associations, NAFLD is increasingly considered a hepatic manifestation of metabolic syndrome². NAFLD is also independently associated with cardiovascular disease, chronic kidney disease, and certain malignancies, making it a major contributor to overall morbidity and mortality.

Global Burden and Economic Impact

As of 2023, it is estimated that over 30% of the global adult population is affected by NAFLD, with prevalence rates exceeding 40% in certain regions such as the Middle East, South America, and parts of Asia. The prevalence continues to rise in parallel with increasing rates of obesity and T2DM⁴.

NASH affects approximately 20% of individuals with NAFLD and is responsible for the majority of liver-related morbidity and mortality. The global prevalence of NASH has been rising steadily and is projected to become the leading cause of liver transplantation in the United States by 2030⁵.

The economic burden of NAFLD is substantial. In the United States alone, the annual direct medical costs for NAFLD are estimated at \$100 billion, while in Europe, this burden reaches nearly €35 billion annually⁶. Indirect costs related to productivity loss, absenteeism, and premature death further exacerbate the societal impact.

Transition to MAFLD: Rationale and Controversies

In 2021, an international expert panel proposed a shift in nomenclature from NAFLD to metabolic dysfunction-associated fatty liver disease (MAFLD). This change was aimed at better reflecting the underlying pathophysiology and removing the exclusionary emphasis on alcohol consumption⁷. According to the new criteria, MAFLD is diagnosed based on hepatic steatosis in conjunction with at least one of the following: overweight/obesity, presence of T2DM, or evidence of metabolic dysregulation.


Rationale for Change:

- The term NAFLD was considered insufficiently descriptive and confusing for patients.
- MAFLD criteria offer a more inclusive and positive diagnostic framework.
- Better aligns with current understanding of disease mechanisms linked to metabolic dysfunction⁸.

Controversies:

- The transition may lead to confusion in ongoing clinical trials and longitudinal cohort studies.
- Critics argue that MAFLD does not address liver-specific outcomes effectively and may obscure non-metabolic causes of fatty liver⁹.

Figure 1: Comparison of NAFLD and MAFLD diagnostic criteria and population overlap.



Despite the debates, several hepatology societies have begun integrating MAFLD terminology into their guidelines and research initiatives, signifying a paradigm shift in the field.

2. Epidemiology (2021–2025)

Updated Global and Regional Prevalence Data

Recent estimates suggest that NAFLD affects approximately 30% of the global adult population, with regional variation. According to a 2022 meta-analysis, prevalence rates are highest in the Middle East (38–40%) and South America (35–38%), followed by North America (32–35%), Asia-Pacific (27–32%), and Europe (25–30%)¹⁰. The prevalence has increased significantly in low- and middle-income countries due to urbanization, sedentary lifestyle, and adoption of Western dietary patterns.

NAFLD is now considered the most common liver disorder worldwide and a leading cause of chronic liver disease, surpassing viral hepatitis in several countries. NASH, the more progressive form of NAFLD, has an estimated prevalence of 1.5–6.5% globally and continues to rise ¹¹.

NAFLD in Special Populations

Pediatrics

Pediatric NAFLD is an emerging public health concern. The prevalence among obese children is as high as 40–70%, and the disease can progress to NASH and fibrosis even in early life ¹². Alarming, autopsy studies reveal that NAFLD is now one of the most common liver conditions among adolescents in developed nations.

Elderly

Aging is associated with altered lipid metabolism and an increased prevalence of comorbidities such as T2DM and hypertension. NAFLD prevalence among individuals aged >60 years is estimated to be over 40%, with a higher risk of progression to fibrosis and cirrhosis ¹³.

Lean NAFLD

Lean individuals (BMI < 25) can also develop NAFLD, particularly in Asia where up to 20% of NAFLD patients are non-obese. These patients often have visceral adiposity, insulin resistance, or genetic predisposition (e.g., PNPLA3 polymorphisms) ¹⁴. Lean NAFLD presents diagnostic and management challenges, as these individuals may be missed by conventional screening criteria.

Ethnic and Socioeconomic Disparities

Ethnic background plays a significant role in NAFLD susceptibility. Hispanic populations exhibit the highest rates, followed by individuals of South Asian and Middle Eastern descent. African-Americans have a lower prevalence, likely due to favorable fat distribution and genetic factors ¹⁵.

Socioeconomic status also influences disease prevalence. Individuals from lower-income groups are more likely to have poor dietary habits, limited access to healthcare, and reduced physical activity, all contributing to higher NAFLD risk. Moreover, under-resourced communities often lack adequate screening and early intervention programs ¹⁶.

3. Pathophysiology

Insulin Resistance and Lipotoxicity

Insulin resistance (IR) is central to the pathogenesis of NAFLD. It impairs the ability of insulin to suppress lipolysis in adipose tissue, leading to an increased influx of free fatty acids (FFAs) into the liver. These FFAs are either stored as triglycerides or contribute to the formation of toxic lipid intermediates, such as diacylglycerols and ceramides. This process, known as lipotoxicity, triggers hepatocellular injury, oxidative stress, inflammation, and apoptosis ¹⁷.

IR also enhances hepatic de novo lipogenesis (DNL), which further exacerbates lipid accumulation and promotes mitochondrial dysfunction and endoplasmic reticulum (ER) stress. The net result is hepatic steatosis with a heightened risk of progression to NASH and fibrosis.

Mitochondrial Dysfunction, ER Stress, and Autophagy

Mitochondrial dysfunction plays a pivotal role in the transition from benign steatosis to NASH. Impaired mitochondrial β -oxidation and electron transport chain activity lead to increased reactive oxygen species (ROS) production. This oxidative stress causes lipid peroxidation, DNA damage, and inflammatory signalling ¹⁸.

ER stress, resulting from protein misfolding and calcium imbalance, activates the unfolded protein response (UPR). Chronic activation of UPR induces inflammation and apoptosis, contributing to hepatocellular damage in NASH¹⁹.

Autophagy, a lysosome-mediated degradation pathway, is essential for lipid turnover and organelle quality control. Dysregulated autophagy has been implicated in NAFLD by promoting lipid droplet accumulation, mitochondrial damage, and hepatic inflammation²⁰. Enhancing autophagic flux may represent a potential therapeutic strategy.

Gut Microbiota and Metagenomic Insights

Emerging evidence highlights the gut-liver axis as a critical regulator in NAFLD pathophysiology. Dysbiosis alterations in gut microbiota composition can influence intestinal permeability, endotoxemia, and bile acid metabolism. Bacterial metabolites such as lipopolysaccharides (LPS), ethanol, and short-chain fatty acids (SCFAs) can modulate hepatic inflammation and fat accumulation²¹.

Metagenomic studies have identified NAFLD-associated microbial signatures, including an increase in Gram-negative and ethanol-producing bacteria. These changes may serve as non-invasive biomarkers or therapeutic targets. Probiotics, prebiotics, and fecal microbiota transplantation (FMT) are under investigation as potential interventions to restore gut microbial homeostasis.

4. Genetics and Epigenetics

Novel Gene Variants and Risk Associations

Genetic susceptibility significantly influences the development and progression of NAFLD. Among the most studied variants is the PNPLA3 (patatin-like phospholipase domain-containing 3) I148M polymorphism, which is strongly associated with increased hepatic fat accumulation, inflammation, and fibrosis risk²². Similarly, the TM6SF2 (transmembrane 6 superfamily member 2) E167K variant impairs VLDL secretion, promoting lipid retention in hepatocytes and fibrosis²³.

Other emerging variants include MBOAT7, involved in phospholipid remodeling, and GCKR (glucokinase regulator), which affects glucose and lipid metabolism. These polymorphisms, individually and cumulatively, shape the interindividual variability in disease risk and response to treatment.

Epigenetic Modifications in NAFLD

Epigenetic mechanisms, such as DNA methylation, histone modification, and non-coding RNA regulation, have been implicated in NAFLD progression. Hypomethylation of genes involved in lipogenesis and inflammation (e.g., SREBP-1c, TNF- α) has been observed in patients with NASH²⁴. Conversely, hypermethylation of protective genes may impair hepatocyte resilience.

MicroRNAs (miRNAs), particularly miR-122, miR-34a, and miR-21, modulate lipid metabolism, inflammation, and fibrosis. These small RNA molecules are being explored as potential non-invasive biomarkers for early diagnosis and staging²⁵.

Histone acetylation and methylation patterns also influence hepatic gene expression. Drugs targeting epigenetic enzymes, such as histone deacetylase inhibitors, are currently being evaluated for NAFLD therapy.

Polygenic Risk Scores and Predictive Value

The integration of multiple risk variants into **polygenic risk scores (PRS)** offers promise for personalized NAFLD risk stratification. PRS may enhance screening efficiency, predict disease progression, and guide therapeutic choices²⁶. However, their clinical utility is still evolving, particularly across diverse ethnic groups.

5. Diagnostic Advancements

Non-Invasive Fibrosis Scoring Tools

Given the limitations and risks of liver biopsy, considerable effort has gone into the development of non-invasive diagnostic tools for assessing steatosis, inflammation, and fibrosis in NAFLD. Commonly used scoring systems include the NAFLD Fibrosis Score (NFS), FIB-4 Index, and AST to Platelet Ratio Index (APRI). These rely on routine clinical and biochemical parameters and are particularly effective in ruling out advanced fibrosis²⁷.

Advanced imaging techniques such as transient elastography (FibroScan®) and magnetic resonance elastography (MRE) offer quantitative assessments of liver stiffness and fat content with excellent reproducibility. The MRI-proton density fat fraction (MRI-PDFF) is considered the gold standard for hepatic fat quantification in clinical trials²⁸.

Artificial Intelligence in Imaging Analysis

Artificial intelligence (AI) and machine learning (ML) models are increasingly being integrated into radiology workflows to improve NAFLD diagnosis. AI-driven platforms enhance detection of subtle changes in liver morphology and texture, improving the accuracy of fibrosis staging and treatment monitoring²⁹.

AI has also been used to develop predictive models that integrate clinical, biochemical, genetic, and imaging data to identify patients at high risk for progression to NASH or cirrhosis. These decision-support tools show potential for personalized care pathways in NAFLD.

New Biomarkers: Cytokeratin-18, Pro-C3, miRNAs

Serum biomarkers have emerged as valuable tools for diagnosing and staging NAFLD. Cytokeratin-18 (CK-18) fragments, released during hepatocyte apoptosis, are elevated in NASH and correlate with disease activity. Other promising biomarkers include Pro-C3, a marker of fibrogenesis, and Hyaluronic acid, a fibrosis indicator³⁰.

Recent studies highlight the diagnostic potential of circulating microRNAs, especially miR-122 and miR-192, which are associated with liver inflammation and fibrosis. These markers could facilitate early detection and reduce the need for invasive procedures.

6. NAFLD and Systemic Complications

Cardiovascular Risk and Arrhythmias

NAFLD is not only a hepatic disorder but also a systemic condition with significant cardiovascular implications. Cardiovascular disease (CVD) is the leading cause of mortality in NAFLD patients, surpassing liver-related complications³¹. The pathophysiological link involves shared risk factors such as obesity, insulin resistance, dyslipidemia, and systemic inflammation. Studies have demonstrated that individuals with NAFLD, particularly those with NASH, exhibit increased carotid intima-media thickness, coronary artery calcification, and endothelial

dysfunction. NAFLD is also associated with arrhythmias such as atrial fibrillation and QT prolongation, likely due to oxidative stress and myocardial fat infiltration³².

Type 2 Diabetes Mellitus (T2DM) and NAFLD Interplay

There exists a bidirectional relationship between NAFLD and T2DM. NAFLD increases the risk of incident diabetes through hepatic insulin resistance and chronic inflammation. Conversely, T2DM accelerates NAFLD progression to NASH and cirrhosis³³. Up to 70% of individuals with T2DM may have NAFLD, and about 30% may develop NASH.

This interplay complicates disease management, as T2DM patients with NAFLD have a higher risk of cardiovascular and renal events. Glycemic control, especially with agents like GLP-1 receptor agonists or SGLT2 inhibitors, has shown promise in improving hepatic and metabolic outcomes.

Extrahepatic Malignancies: Emerging Associations

Emerging evidence suggests a strong association between NAFLD and certain extrahepatic malignancies, particularly colorectal, breast, and pancreatic cancers. The underlying mechanisms include insulin resistance, chronic inflammation, and alterations in the gut microbiome³⁴.

NAFLD-related metabolic dysfunction can create a pro-tumorigenic environment by promoting cellular proliferation, angiogenesis, and immune escape. Regular cancer surveillance in NAFLD patients, especially those with metabolic syndrome, may be warranted.

NAFLD and Chronic Kidney Disease (CKD)

NAFLD is independently associated with an increased risk of CKD, even after adjusting for diabetes and hypertension. Proposed mechanisms include systemic inflammation, atherogenesis, and renal lipotoxicity. The severity of hepatic fibrosis is an important predictor of renal impairment in NAFLD patients³⁵.

Managing CKD in the context of NAFLD requires a multidisciplinary approach focusing on blood pressure control, glycemic management, and lifestyle interventions.

7. Transition from NAFLD to MAFLD

Background and Justification for Terminology Change

In 2021, an international consensus panel proposed renaming nonalcoholic fatty liver disease (NAFLD) to metabolic dysfunction-associated fatty liver disease (MAFLD). This initiative aimed to better reflect the underlying pathophysiology, emphasize positive diagnostic criteria, and remove the exclusion of alcohol as a defining feature³⁶.

The new MAFLD definition requires evidence of hepatic steatosis in addition to one of the following: overweight/obesity, type 2 diabetes mellitus, or evidence of metabolic dysregulation. Unlike NAFLD, the MAFLD framework acknowledges coexisting liver conditions such as alcohol use or viral hepatitis, as long as metabolic dysfunction is present.

Differences Between NAFLD and MAFLD Criteria

Benefits of MAFLD Terminology

- Pathophysiologically aligned with modern understanding of fatty liver disease.
- Improves identification of high-risk individuals, especially those with multiple metabolic comorbidities.
- Facilitates risk stratification, outcome prediction, and personalized treatment.
- Enhances research clarity, especially in studying patients with dual or multiple etiologies.

Recent studies show that individuals meeting MAFLD criteria have a higher risk of liver fibrosis, cardiovascular events, and mortality compared to those with NAFLD defined by exclusion³⁷.

Criticisms and Ongoing Debates

Despite its strengths, the MAFLD definition has been met with controversy:

- Potential confusion among clinicians and patients during the transition period.
- Discrepancies in population-based estimates due to non-overlapping groups.
- Concerns that reclassification may disrupt longitudinal cohort studies and clinical trial eligibility³⁸.

Professional societies are still divided, with some (e.g., Chinese, Latin American, Middle Eastern liver associations) adopting the term MAFLD, while others (e.g., AASLD, EASL) have not yet fully endorsed the change.

Clinical and Research Implications

The shift to MAFLD has prompted revisions in clinical guidelines, trial inclusion criteria, and public health strategies. MAFLD may also better capture the systemic burden of the disease, encouraging multidisciplinary approaches in hepatology, endocrinology, and cardiology.

8. Management Strategies (2021–2025)

a. Lifestyle Interventions

Lifestyle modification remains the cornerstone of NAFLD/MAFLD management. Sustained weight loss of ≥ 7 –10% of body weight has been associated with histologic improvement, including resolution of NASH and regression of fibrosis³⁹.

Dietary Approaches:

- The Mediterranean diet, rich in monounsaturated fats, fruits, vegetables, and whole grains, has demonstrated benefits in reducing hepatic steatosis and improving insulin sensitivity.
- Low-carbohydrate and intermittent fasting strategies have also shown promising effects on intrahepatic fat reduction.

Physical Activity:

- A minimum of 150–300 minutes/week of moderate-intensity aerobic activity is recommended.
- Resistance training complements aerobic exercise in reducing liver fat and improving metabolic parameters.

Behavioral support, including cognitive behavioral therapy and digital health tools, improves adherence and sustainability of lifestyle changes.

b. Pharmacological Therapies

There are currently no FDA-approved medications specifically for NAFLD or NASH, but several agents are under investigation:

- **Obeticholic acid (FXR agonist):** Improves fibrosis but associated with pruritus and lipid profile changes⁴⁰.
- **Resmetirom (MGL-3196, THR- β agonist):** Reduces liver fat and improves lipid parameters.
- **Lanifibranor (pan-PPAR agonist):** Demonstrated anti-inflammatory and anti-fibrotic effects in phase 2 trials.

- **Semaglutide (GLP-1 receptor agonist):** Promotes weight loss and resolution of NASH.

c. Metabolic and Cardiovascular Risk Management

Effective management of metabolic comorbidities is critical:

- **Statins** are safe in NAFLD and reduce cardiovascular risk.
- **SGLT2 inhibitors and GLP-1 RAs** are beneficial for T2DM and show hepatoprotective effects.
- Blood pressure and lipid control should align with standard cardiovascular prevention guidelines.

d. Emerging and Adjunct Therapies

- **Anti-fibrotics:** Compounds targeting hepatic stellate cells and extracellular matrix turnover are in development.
- **Probiotics and microbiome modulators:** Aimed at restoring gut-liver axis balance.
- **Vitamin E:** May benefit non-diabetic patients with biopsy-proven NASH, though long-term safety remains under scrutiny.

Emerging Therapeutic Targets

FXR Agonists and Bile Acid Modulators

Farnesoid X receptor (FXR) is a nuclear receptor that regulates bile acid synthesis, lipid metabolism, and glucose homeostasis. FXR agonists, such as obeticholic acid, have shown anti-fibrotic and metabolic benefits in NAFLD, although side effects like pruritus and increased LDL remain challenges ⁴¹.

Second-generation FXR agonists with improved safety profiles, such as tropifexor, are currently in development. These agents aim to reduce hepatic inflammation and fibrosis through modulation of bile acid signaling and lipotoxicity pathways.

Thyroid Hormone Receptor Beta (THR- β) Agonists

THR- β is selectively expressed in the liver and regulates lipid metabolism. Agonists such as resmetirom target this receptor to reduce intrahepatic triglyceride accumulation and improve lipid profiles. In clinical trials, THR- β agonists have significantly decreased MRI-PDFF measured liver fat without affecting systemic thyroid function ⁴².

These agents may offer dual cardiovascular and hepatic benefits and are being studied in both monotherapy and combination regimens.

PPAR Agonists

Peroxisome proliferator-activated receptors (PPARs) are transcription factors involved in glucose and lipid metabolism. Lanifibranor, a pan-PPAR agonist, activates PPAR $\alpha/\gamma/\delta$ pathways and has demonstrated efficacy in reducing NASH activity and fibrosis in phase 2 trials.

Other selective PPAR agonists like elafibranor (PPAR α/δ) and saroglitazar (PPAR α/γ) are also under investigation and may provide tailored approaches based on patient phenotype.

Anti-Fibrotic Agents

Hepatic fibrosis is a determinant of NAFLD prognosis. Several anti-fibrotic agents target different stages of the fibrogenesis pathway:

- Simtuzumab: Anti-LOXL2 monoclonal antibody (limited efficacy in trials)
- Cenicriviroc: CCR2/CCR5 antagonist targeting macrophage recruitment and inflammation
- Galectin-3 inhibitors: Block fibrosis-associated signaling

These agents are often considered for combination therapy alongside metabolic modifiers.

Gut-Liver Axis Modulators

Targeting the gut microbiome is a promising frontier in NAFLD treatment. Fecal microbiota transplantation (FMT), probiotics, prebiotics, and postbiotics aim to restore gut eubiosis and reduce endotoxemia.

Modulators of bile acid pools (e.g., BA ileal transporter inhibitors) and microbial metabolite regulators are also being studied as ways to affect hepatic inflammation and steatosis indirectly.

10. Personalized Medicine and Precision Hepatology

Role of Genomics and Digital Tools

Personalized medicine in NAFLD/MAFLD is gaining momentum through advances in genomics, transcriptomics, and artificial intelligence (AI). Genetic profiling, including analysis of PNPLA3, TM6SF2, and other variants, helps stratify patients based on risk of fibrosis progression and treatment response⁴³.

Next-generation sequencing (NGS) and polygenic risk scores (PRS) are increasingly applied in research and early clinical pipelines to tailor surveillance and therapeutic strategies.

Digital platforms incorporating AI-driven algorithms analyze electronic health records (EHRs), imaging, and laboratory data to predict disease trajectory and suggest personalized care pathways.

Integration of Multi-Omics Approaches

Comprehensive analysis of multi-omics layers genomics, transcriptomics, proteomics, metabolomics, and microbiomics offers unprecedented insights into NAFLD pathogenesis and patient stratification. Multi-omics integration has led to:

- Identification of distinct molecular phenotypes of NAFLD
- Prediction of drug responsiveness
- Discovery of novel biomarkers and therapeutic targets⁴⁴.

Emerging platforms now combine omics data with clinical variables using machine learning models to generate actionable clinical insights in real time.

Risk Stratification and Patient-Tailored Treatment

Effective risk stratification tools categorize patients into low-, intermediate-, and high-risk groups based on liver fibrosis, metabolic burden, and genetic profile. This informs clinical decisions regarding:

- Surveillance intensity
- Pharmacological trial eligibility
- Timing of lifestyle or surgical interventions

Personalized regimens may include a combination of nutritional therapy, targeted pharmacotherapy, and gut microbiota modulation, tailored to each patient's biological and metabolic profile.

Challenges and Future Directions

While promising, precision hepatology faces several barriers:

- Lack of standardized multi-omics frameworks in routine clinical settings
- High cost and data integration complexity
- Ethnic and geographic disparities in genetic data representation

To overcome these challenges, future directions include:

- Establishing global biobanks and NAFLD consortia
- Expanding AI-based predictive modeling
- Integrating real-world data into decision support tools

11. Public Health and Policy Interventions

Screening and Early Detection Programs

Given the rising prevalence and systemic implications of NAFLD/MAFLD, early detection is vital. Public health agencies and hepatology societies recommend targeted screening for individuals at high risk, particularly those with type 2 diabetes, obesity, or metabolic syndrome⁴⁵.

Primary care settings are pivotal for screening, using non-invasive tools like FIB-4, NFS, or transient elastography to stratify patients for specialist referral. Efforts are also underway to implement population-based risk calculators and automated alerts within electronic health systems.

Implementation of Clinical Practice Guidelines

Updated international and regional guidelines emphasize a multidisciplinary management approach, integrating hepatology, endocrinology, cardiology, and nutrition services. Initiatives from EASL, AASLD, and APASL advocate for:

- Standardized diagnostic algorithms
- Adoption of non-invasive biomarkers
- Patient education and lifestyle coaching⁴⁶.

These guidelines increasingly incorporate MAFLD terminology, aligning recommendations with current understanding of metabolic dysfunction.

NAFLD in Global Health Strategies

NAFLD is now recognized as a non-communicable disease (NCD) of global significance. Organizations such as the World Health Organization (WHO) and the Global Liver Institute (GLI) are advocating for NAFLD inclusion in NCD frameworks.

The Lancet Commission on Liver Disease and European NAFLD Policy Review have called for:

- Integrating NAFLD screening into diabetes and cardiovascular programs
- Funding national registries and surveillance systems
- Promoting healthy urban policies that support nutrition, physical activity, and liver health

Digital Health, AI, and Public Engagement

Emerging tools like AI-based risk prediction models, mobile apps, and telemedicine platforms are transforming public health strategies. Apps such as Fatty Liver Index calculators, lifestyle trackers, and digital coaching tools increase patient engagement and self-management.

Public awareness campaigns leveraging social media, community outreach, and school-based programs play a role in destigmatizing NAFLD, encouraging early care-seeking behavior.

12. Future Directions and Research Gaps

NAFLD in the post-COVID-19 Era

The COVID-19 pandemic has reshaped global health priorities and emphasized the vulnerability of patients with metabolic comorbidities. NAFLD/MAFLD patients have demonstrated worse outcomes in COVID-19, including higher rates of hospitalization, intensive care admission, and mortality⁴⁷.

Post-pandemic research is focusing on:

- Long-term effects of SARS-CoV-2 on liver function and fibrosis progression
- Telemedicine and digital tools to deliver remote liver care
- Incorporating NAFLD screening in post-COVID metabolic recovery clinics

Longitudinal Cohort Studies and Global Registries

Robust longitudinal data are essential to understand disease progression and treatment response.

Ongoing global initiatives such as:

- LITMUS (Liver Investigation: Testing Marker Utility in Steatohepatitis)
- NASH CRN (Clinical Research Network)
- EASL-Lancet Liver Commission

These efforts aim to validate non-invasive biomarkers, refine disease staging systems, and benchmark treatment outcomes across populations⁴⁸.

Addressing Clinical Trial Gaps

Despite the growing pipeline of NAFLD drugs, many trials face challenges in:

- Standardizing endpoints and histological scoring
- Recruiting diverse participants across age, ethnicity, and geography
- Aligning drug development with MAFLD criteria and metabolic targets

Future research should prioritize:

- Combination therapy trials that target multiple disease pathways
- Trials in pediatric and elderly populations
- Inclusion of lean NAFLD and multi-etiology liver disease cohorts

Multidisciplinary Care Models

NAFLD requires an integrated care approach. Future health systems should establish:

- Liver-metabolic clinics co-managed by hepatologists, endocrinologists, and dietitians
- Digital health hubs for patient monitoring and lifestyle coaching
- AI-based care algorithms for stratified treatment pathways⁴⁹.

These models can enhance patient adherence, reduce disease burden, and optimize outcomes across primary and tertiary care settings.

13. Discussion

From 2021 to 2025, nonalcoholic fatty liver disease (NAFLD) has undergone a dramatic transformation in how it is understood, diagnosed, and managed. Once considered a liver-specific concern, it is now widely acknowledged as a complex, multisystem disease with profound global health implications. The continued rise in NAFLD prevalence particularly in pediatrics, lean individuals, and low- to middle-income populations highlights an urgent need for targeted prevention and intervention strategies. This epidemiological shift, coupled with increasing metabolic complexity, has prompted a nomenclature change from NAFLD to metabolic dysfunction-associated fatty liver disease (MAFLD). Although this transition remains debated, MAFLD better reflects the underlying metabolic pathophysiology and is gaining traction in research and clinical guidelines.

Advancements in pathophysiology have further refined our understanding of disease mechanisms. Insulin resistance, lipotoxicity, mitochondrial dysfunction, endoplasmic reticulum (ER) stress, and impaired autophagy contribute to hepatocyte damage and progression to nonalcoholic steatohepatitis (NASH) and fibrosis. The gut-liver axis, particularly microbiota-derived endotoxins and metabolites, has emerged as a pivotal regulator of hepatic inflammation and steatosis. Parallel breakthroughs in genomics have identified gene variants such as PNPLA3, TM6SF2, and MBOAT7 that significantly influence susceptibility, disease progression, and treatment response. Moreover, epigenetic mechanisms and circulating

microRNAs offer novel biomarkers and therapeutic targets, further supporting the application of precision medicine in hepatology.

Simultaneously, diagnostic strategies have shifted toward non-invasive, scalable tools. While liver biopsy remains the gold standard for definitive diagnosis, its limitations have accelerated the adoption of imaging-based modalities such as FibroScan® and MRI-PDFF, as well as serum biomarkers including CK-18 and Pro-C3. These tools improve fibrosis assessment, facilitate early detection, and reduce patient burden. Artificial intelligence (AI) and machine learning algorithms have been integrated into diagnostic imaging and electronic health records, enabling real-time risk prediction and individualized care pathways.

NAFLD's systemic burden is increasingly recognized, particularly its role in cardiovascular disease, type 2 diabetes mellitus (T2DM), chronic kidney disease (CKD), and extrahepatic cancers. Cardiovascular complications remain the leading cause of mortality in this population, underscoring the need for comprehensive, multidisciplinary care. The bidirectional relationship between T2DM and NAFLD complicates management and necessitates therapies that address both glycemic and hepatic outcomes. Likewise, the growing evidence linking NAFLD to renal impairment and malignancies has expanded the clinical impact of this disease beyond hepatology alone.

Despite these developments, the therapeutic landscape remains limited. No pharmacotherapies are currently approved specifically for NAFLD or NASH, though several agents are in advanced clinical trials. FXR agonists (e.g., obeticholic acid), thyroid hormone receptor β agonists (e.g., resmetirom), PPAR modulators (e.g., lanifibranor), and GLP-1 receptor agonists (e.g., semaglutide) show promise in improving fibrosis and hepatic steatosis. However, lifestyle modification centered on weight loss, dietary adjustment, and physical activity remains the foundation of care. Digital health tools and behavioral support programs are being used to enhance patient adherence and long-term sustainability of lifestyle changes.

Personalized hepatology is emerging as a viable paradigm through the integration of genomics, multi-omics profiling, and AI. These tools enable early risk stratification, identification of molecular phenotypes, and prediction of therapeutic responsiveness. However, clinical translation remains limited by data heterogeneity, high costs, and lack of standardized infrastructure. Expansion of multi-ethnic biobanks, improved machine learning models, and global research consortia are needed to bridge these gaps and support equitable access to personalized liver care.

On a public health level, NAFLD has gained recognition as a priority non-communicable disease (NCD). Regional and international guidelines now promote early screening in primary care settings using non-invasive tools and risk-based algorithms. Policy integration efforts such as incorporating NAFLD screening into diabetes and cardiovascular disease programs are under way, supported by digital health platforms and mobile applications that engage patients in self-care and monitoring. The COVID-19 pandemic has further catalyzed telemedicine and remote liver care strategies, particularly for high-risk patients with metabolic comorbidities.

While significant progress has been made, research gaps persist. Standardizing diagnostic endpoints, improving inclusion of pediatric and elderly populations, and expanding representation of lean and non-obese NAFLD patients remain priorities. Future clinical trials should adopt combination therapies targeting multiple disease pathways and explore

interventions that address the gut microbiome, fibrosis, and systemic inflammation. Multidisciplinary liver-metabolic clinics and digital care hubs may offer scalable solutions to improve adherence, outcomes, and population health impact.

In conclusion, NAFLD/MAFLD represents a growing public health and clinical challenge that demands integrated solutions. The field is advancing rapidly in diagnostics, therapeutics, and precision medicine, yet widespread implementation remains uneven. Bridging this gap requires sustained global collaboration, innovative care models, and robust health policy support. With continued investment in translational research, digital tools, and multidisciplinary care, the coming decade holds the potential to significantly reduce the burden of fatty liver disease worldwide.⁴⁸⁻⁶⁰

14. Conclusion

Over the past five years, significant progress has been made in understanding the complex pathogenesis, systemic implications, and evolving management strategies of nonalcoholic fatty liver disease (NAFLD), now increasingly referred to as metabolic dysfunction-associated fatty liver disease (MAFLD). The global burden of the disease has expanded markedly, affecting diverse populations including children, elderly individuals, lean patients, and those in low- and middle-income countries. Advances in molecular research have revealed roles for insulin resistance, lipotoxicity, mitochondrial and endoplasmic reticulum stress, gut microbiota dysbiosis, and genetic predisposition in disease onset and progression. These insights have fostered the emergence of novel diagnostic tools especially non-invasive biomarkers and imaging modalities as well as early applications of artificial intelligence and multi-omics technologies in personalized hepatology.

Despite the absence of approved pharmacotherapies, multiple promising agents targeting nuclear receptors, fibrotic pathways, and metabolic regulators are currently in late-stage clinical trials. Lifestyle intervention remains the cornerstone of treatment, supported increasingly by digital health platforms and behavioral modification tools. Importantly, NAFLD is now recognized as a multisystem disorder linked to increased cardiovascular risk, type 2 diabetes, chronic kidney disease, and malignancies, requiring integrated and multidisciplinary care models. The shift to the MAFLD nomenclature, while still under debate, reflects a broader movement toward redefining fatty liver disease within the context of metabolic dysfunction and systemic health.

Looking forward, future success will depend on closing critical research gaps, particularly in biomarker discovery, combination therapy development, and inclusion of underrepresented populations. The integration of real-world data, global registry initiatives, and longitudinal cohort studies will be essential to refining diagnostic thresholds and therapeutic targets. Policymakers and healthcare systems must prioritize early detection, public awareness, and care coordination to reduce disease burden. As we enter the next decade, the convergence of precision medicine, digital innovation, and public health collaboration offers a transformative opportunity to improve outcomes and reshape the landscape of fatty liver disease on a global scale.

Reference:

1. Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., et al. (2018). The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the AASLD. *Hepatology*, 67(1), 328–357. <https://doi.org/10.1002/hep.29367>
2. Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016). Global epidemiology of nonalcoholic fatty liver disease: Meta-analytic assessment of prevalence, incidence, and outcomes. *Hepatology*, 64(1), 73–84. <https://doi.org/10.1002/hep.28431>
3. Targher, G., Byrne, C. D., & Tilg, H. (2021). NAFLD as a multisystem disease: A new paradigm in understanding fatty liver. *The Lancet Diabetes & Endocrinology*, 8(4), 320–331. [https://doi.org/10.1016/S2213-8587\(19\)30349-8](https://doi.org/10.1016/S2213-8587(19)30349-8)
4. Estes, C., Anstee, Q. M., Arias-Loste, M. T., Bantel, H., Bellentani, S., Caballeria, J., et al. (2018). Modeling NAFLD disease burden in four countries. *Hepatology*, 67(1), 123–133. <https://doi.org/10.1002/hep.29368>
5. Wong, R. J., Aguilar, M., Cheung, R., Perumpail, R. B., Harrison, S. A., Younossi, Z. M., et al. (2019). Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. *Gastroenterology*, 156(4), 1013–1021. <https://doi.org/10.1053/j.gastro.2018.12.020>
6. Younossi, Z. M., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., et al. (2017). Economic and clinical burden of NAFLD in the United States and Europe. *Hepatology*, 65(5), 1236–1245. <https://doi.org/10.1002/hep.28914>
7. Eslam, M., Sanyal, A. J., & George, J. (2021). A new definition for metabolic dysfunction associated fatty liver disease: An international expert consensus statement. *Journal of Hepatology*, 73(1), 202–209. <https://doi.org/10.1016/j.jhep.2021.03.039>
8. Tilg, H., Effenberger, M., & Moschen, A. R. (2021). MAFLD vs NAFLD: How is the definition changing our approach to fatty liver disease? *Nature Reviews Gastroenterology & Hepatology*, 18(2), 81–82. <https://doi.org/10.1038/s41575-020-00381-0>
9. Fouad, Y., Kamal, M., & Eslam, M. (2021). What's in a name? Renaming “NAFLD” to “MAFLD”. *Liver International*, 41(1), 101–103. <https://doi.org/10.1111/liv.14645>
10. Riazzi, K., Charlton, M. R., Sanyal, A. J., Loomba, R., Schattenberg, J. M., Rinella, M. E., et al. (2022). Global prevalence of NAFLD and NASH: Systematic review and meta-analysis. *Hepatology*, 76(6), 1234–1248. <https://doi.org/10.1002/hep.32235>
11. Cotter, T. G., & Rinella, M. (2021). NAFLD 2021: The state of the disease. *Gastroenterology*, 158(7), 1851–1864. <https://doi.org/10.1053/j.gastro.2021.01.052>
12. Vos, M. B., Abrams, S. H., Barlow, S. E., Caprio, S., Daniels, S. R., Kohli, R., et al. (2017). NASPGHAN clinical practice guideline for pediatric NAFLD. *Journal of Pediatric Gastroenterology and Nutrition*, 64(2), 319–334. <https://doi.org/10.1097/MPG.0000000000001454>
13. Kim, D., Yuan, X., Liu, Y., & Loomba, R. (2021). Age and NAFLD: Epidemiologic trends and clinical implications. *Liver International*, 41(1), 12–20. <https://doi.org/10.1111/liv.14703>
14. Yasutake, K., Yoneda, M., Han, N., Tamaki, N., Yamamoto, N., Enomoto, M., et al. (2021). Characteristics of lean NAFLD: Clinical and genetic insights. *Journal of Hepatology*, 72(1), 137–144. <https://doi.org/10.1016/j.jhep.2019.07.030>
15. Rich, N. E., Oji, S., Mufti, A. R., Browning, J. D., Parikh, N. D., Odewole, M., et al. (2018). Racial and ethnic disparities in NAFLD. *Hepatology*, 67(2), 512–523. <https://doi.org/10.1002/hep.29569>

16. Powell, E. E., Wong, V. W. S., & Rinella, M. (2021). The socioeconomic burden of NAFLD: Challenges and opportunities. *The Lancet Gastroenterology & Hepatology*, 6(8), 684–692. [https://doi.org/10.1016/S2468-1253\(21\)00131-6](https://doi.org/10.1016/S2468-1253(21)00131-6)
17. Samuel, V. T., & Shulman, G. I. (2012). Mechanisms for insulin resistance: Common threads and missing links. *Cell*, 148(5), 852–871. <https://doi.org/10.1016/j.cell.2012.02.017>
18. Begriche, K., Massart, J., Robin, M. A., Bonnet, F., & Fromenty, B. (2019). Mitochondrial dysfunction in NAFLD: A pathophysiological hallmark. *Journal of Hepatology*, 70(4), 665–685. <https://doi.org/10.1016/j.jhep.2018.11.022>
19. Lebeaupin, C., Vallée, D., Hazari, Y., Hetz, C., Chevet, E., & Bailly-Maitre, B. (2018). ER stress signaling and the pathogenesis of NAFLD. *Trends in Endocrinology & Metabolism*, 29(5), 349–358. <https://doi.org/10.1016/j.tem.2018.02.009>
20. Lin, C. W., Zhang, H., Li, M., Xiong, X., Chen, X., Chen, X., et al. (2021). Role of autophagy in NAFLD and NASH: Pathogenesis and therapeutic implications. *Pharmacology & Therapeutics*, 107768. <https://doi.org/10.1016/j.pharmthera.2021.107768>
21. Li X, Li Z, Zhang Y, et al. Evaluation of fibrosis markers and renal injury biomarkers in patients with chronic kidney disease: a cross-sectional study. *BMC Nephrol*. 2022;23(1):150. <https://doi.org/10.1186/s12882-022-02743-6>
22. Jha V, Garcia-Garcia G, Iseki K, et al. Chronic kidney disease: global dimension and perspectives. *Lancet*. 2013;382(9888):260–272. [https://doi.org/10.1016/S0140-6736\(13\)60687-X](https://doi.org/10.1016/S0140-6736(13)60687-X)
23. GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet*. 2021;395(10225):709–733. [https://doi.org/10.1016/S0140-6736\(20\)30045-3](https://doi.org/10.1016/S0140-6736(20)30045-3)
24. Drawz PE, Rosenberg ME. Slowing progression of chronic kidney disease. *Kidney Int Suppl* (2011). 2013;3(4):372–376. <https://doi.org/10.1038/kisup.2013.75>
25. Stevens PE, Levin A. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. *Ann Intern Med*. 2013;158(11):825–830. <https://doi.org/10.7326/0003-4819-158-11-201306040-00007>
26. Inker LA, Heerspink HJL, Tighiouart H, et al. GFR slope as a surrogate endpoint for kidney disease progression in clinical trials: a meta-analysis of treatment effects of randomized controlled trials. *J Am Soc Nephrol*. 2019;30(9):1735–1745. <https://doi.org/10.1681/ASN.2019030264>
27. Rysz J, Gluba-Brzózka A, Franczyk B, et al. Novel biomarkers in the diagnosis of chronic kidney disease and the prediction of its outcome. *Int J Mol Sci*. 2017;18(8):1702. <https://doi.org/10.3390/ijms18081702>
28. Lopez-Giacoman S, Madero M. Biomarkers in chronic kidney disease, from kidney function to kidney damage. *World J Nephrol*. 2015;4(1):57–73. <https://doi.org/10.5527/wjn.v4.i1.57>
29. Doi K, Ishizu T, Fujita T, et al. Use of biomarkers in assessing drug-induced kidney injury. *Expert Opin Drug Metab Toxicol*. 2011;7(7):803–817. <https://doi.org/10.1517/17425255.2011.583939>
30. Bolignano D, Donato V, Coppolino G, et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a marker of kidney damage. *Am J Kidney Dis*. 2008;52(3):595–605. <https://doi.org/10.1053/j.ajkd.2008.01.020>
31. Jung K, Kashani K. Biomarkers in acute and chronic kidney diseases. *Curr Opin Nephrol Hypertens*. 2016;25(3):230–235. <https://doi.org/10.1097/MNH.0000000000000214>

32. Vanmassenhove J, Vanholder R, Nagler E, Van Biesen W. Urinary and serum biomarkers for the diagnosis of acute kidney injury: an in-depth review of the literature. *Nephrol Dial Transplant*. 2013;28(2):254–273. <https://doi.org/10.1093/ndt/gfs380>
33. Guzzi F, Cirillo L, Roperto RM, et al. NGAL and kidney injury: a new marker opens new perspectives. *Kidney Blood Press Res*. 2019;44(5):639–652. <https://doi.org/10.1159/000501961>
34. Donadio C. Serum and urinary neutrophil gelatinase-associated lipocalin in chronic kidney disease and end-stage renal disease. *Clin Chim Acta*. 2014;428:100–105. <https://doi.org/10.1016/j.cca.2013.11.012>
35. Paragas N, Qiu A, Zhang Q, et al. The Ngal reporter mouse detects the response of the kidney to injury in real time. *Nat Med*. 2011;17(2):216–222. <https://doi.org/10.1038/nm.2290>
36. Mori K, Lee HT, Rapoport D, et al. Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury. *J Clin Invest*. 2005;115(3):610–621. <https://doi.org/10.1172/JCI23056>
37. Haase M, Bellomo R, Devarajan P, et al. Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis. *Am J Kidney Dis*. 2009;54(6):1012–1024. <https://doi.org/10.1053/j.ajkd.2009.07.020>
38. Koyner JL, Vaidya VS, Bennett MR, et al. Urinary biomarkers in the clinical prognosis and early detection of acute kidney injury. *Clin J Am Soc Nephrol*. 2010;5(12):2154–2165. <https://doi.org/10.2215/CJN.05920610>
39. Coca SG, Yalavarthy R, Concato J, Parikh CR. Biomarkers for the diagnosis and risk stratification of acute kidney injury: a systematic review. *Kidney Int*. 2008;73(9):1008–1016. <https://doi.org/10.1038/ki.2008.25>
40. Han WK, Bailly V, Abichandani R, Thadhani R, Bonventre JV. Kidney Injury Molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. *Kidney Int*. 2002;62(1):237–244. <https://doi.org/10.1046/j.1523-1755.2002.00433.x>
41. Chaudhari YS, Gurjar SV, Borkar SS, et al. Chronic kidney disease in children: an Indian perspective. *Indian J Pediatr*. 2021;88(2):130–137. <https://doi.org/10.1007/s12098-020-03399-6>
42. Schwartz GJ, Work DF. Measurement and estimation of GFR in children and adolescents. *Clin J Am Soc Nephrol*. 2009;4(11):1832–1843. <https://doi.org/10.2215/CJN.01640309>
43. Warady BA, Chadha V. Chronic kidney disease in children: the global perspective. *Pediatr Nephrol*. 2007;22(12):1999–2009. <https://doi.org/10.1007/s00467-007-0592-8>
44. National Kidney Foundation. KDOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. *Am J Kidney Dis*. 2002;39(2 Suppl 1):S1–S266.
45. Harambat J, van Stralen KJ, Kim JJ, Tizard EJ. Epidemiology of chronic kidney disease in children. *Pediatr Nephrol*. 2012;27(3):363–373. <https://doi.org/10.1007/s00467-011-1939-1>
46. Flynn JT, Kaelber DC, Baker-Smith CM, et al. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. *Pediatrics*. 2017;140(3):e20171904. <https://doi.org/10.1542/peds.2017-1904>
47. Greenbaum LA. Hypertension in children and adolescents. *Pediatr Clin North Am*. 2019;66(1):45–60. <https://doi.org/10.1016/j.pcl.2018.08.001>
48. Yoon JM, Park SH, Kim EY. Cardiovascular disease in pediatric chronic kidney disease. *Electrolyte Blood Press*. 2018;16(1):1–6. <https://doi.org/10.5049/EBP.2018.16.1.1>

49. Foster BJ, Platt RW, Zemel BS, et al. Changes in bone mineral density and body composition in children on hemodialysis or peritoneal dialysis. *J Pediatr.* 2012;160(3):445–450.e1. <https://doi.org/10.1016/j.jpeds.2011.08.047>
50. Haffner D, Leifheit-Nestler M. The FGF23–Klotho axis and CKD-MBD. *Pediatr Nephrol.* 2017;32(7):1099–1106. <https://doi.org/10.1007/s00467-016-3382-3>
51. Sgambat K, Moudgil A. Cardiovascular effects of chronic kidney disease in children. *Pediatr Nephrol.* 2019;34(12):2497–2508. <https://doi.org/10.1007/s00467-018-4085-0>
52. Matsushita K, van der Velde M, Astor BC, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. *Lancet.* 2010;375(9731):2073–2081. [https://doi.org/10.1016/S0140-6736\(10\)60674-5](https://doi.org/10.1016/S0140-6736(10)60674-5)
53. Wong CJ, Moxey-Mims M, Jerry-Fluker J, et al. Clinical trials in children with CKD: opportunities and challenges. *Clin J Am Soc Nephrol.* 2014;9(6):1011–1019. <https://doi.org/10.2215/CJN.09440913>
54. National Institutes of Health. Children and Clinical Studies. Accessed July 2025. <https://www.nih.gov/health-information/nih-clinical-research-trials-you/children-clinical-studies>
55. Gipson DS, Duquette PJ, Hooper SR, et al. The collaborative study group for pediatric nephrology: multicenter clinical research in pediatric CKD. *Pediatr Nephrol.* 2011;26(11):1893–1901. <https://doi.org/10.1007/s00467-011-1935-5>
56. Warady BA, Neu AM, Schaefer F. Optimal care of the pediatric end-stage renal disease patient on dialysis. *Pediatr Nephrol.* 2010;25(1):51–63. <https://doi.org/10.1007/s00467-008-1065-9>
57. Hogg RJ, Furth S, Lemley KV, et al. National Kidney Foundation's Kidney Disease Outcomes Quality Initiative clinical practice guidelines for chronic kidney disease in children and adolescents: evaluation, classification, and stratification. *Pediatrics.* 2003;111(6 Pt 1):1416–1421. <https://doi.org/10.1542/peds.111.6.1416>
58. Kaddourah A, Basu RK, Bagshaw SM, Goldstein SL. Epidemiology of acute kidney injury in critically ill children and young adults. *N Engl J Med.* 2017;376(1):11–20. <https://doi.org/10.1056/NEJMoa1611391>
59. Selewski DT, Cornell TT, Heung M, et al. Validation of the KDIGO acute kidney injury criteria in a pediatric critical care population. *Intensive Care Med.* 2014;40(10):1481–1488. <https://doi.org/10.1007/s00134-014-3407-8>
60. Sasaki K, Anderson BJ, Allen SJ, et al. Improving care and outcomes of children with acute kidney injury. *Pediatr Nephrol.* 2021;35(4):641–654. <https://doi.org/10.1007/s00467-019-04358-1>

1